Table 5.
Other multivalent/bispecific nanobodies with therapeutic potential.
| Nanobody | Disease | Target | Structure features | Year | Reference |
|---|---|---|---|---|---|
| FAF-Nb | Gelsolin amyloidosis | D187N/Y gelsolin/HSA | Bivalent | 2014 | (174) |
| Bispecific | |||||
| Nb22-FAF-Nb | Gelsolin amyloidosis | C68/amyloidogenic gelsolin-fragment | Bivalent | 2017 | (175) |
| Bispecific | |||||
| Everestmab | Type 2 diabetes mellitus | GLP-1R/HSA | Bivalent | 2020 | (176) |
| Bispecific | |||||
| VHH-B11 | Cardiovascular diseases | Low density lipoprotein cholesterol | Bivalent | 2020 | (177) |
| BI-X | Retinal vascular diseases | VEGF/Ang-2/HSA | Multivalent | 2021 | (178) |
| Multi-specific |